📣 VC round data is live. Check it out!
- Public Comps
- IQVIA
IQVIA Valuation Multiples
Discover IQVIA's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Veeva, GE HealthCare, Roper Technologies, Sartorius and more.
IQVIA Overview
About IQVIA
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Founded
2016
HQ

Employees
93.0K
Website
Sectors
Financials (LTM)
EV
$45B
Valuation Multiples
Start free trialIQVIA Financials
IQVIA reported last 12-month revenue of $17B and EBITDA of $4B.
In the same LTM period, IQVIA generated $6B in gross profit, $4B in EBITDA, and $2B in net income.
Revenue (LTM)
IQVIA P&L
In the most recent fiscal year, IQVIA reported revenue of $16B and EBITDA of $4B.
IQVIA is profitable as of last fiscal year, with gross margin of 33%, EBITDA margin of 23%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
IQVIA Stock Performance
IQVIA has current market cap of $31B, and enterprise value of $45B.
Market Cap Evolution
IQVIA's stock price is $186.82.
IQVIA share price increased by 2.5% in the last 30 days, and by 18.5% in the last year.
IQVIA has an EPS (earnings per share) of $12.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45B | $31B | 2.5% | 2.5% | 9.5% | 18.5% | $12.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIQVIA Valuation Multiples
IQVIA trades at 2.7x EV/Revenue multiple, and 11.6x EV/EBITDA.
EV / Revenue (LTM)
IQVIA Financial Valuation Multiples
As of June 2, 2026, IQVIA has market cap of $31B and EV of $45B.
IQVIA has a P/E ratio of 14.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IQVIA Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


IQVIA Margins & Growth Rates
IQVIA grew revenue by 6% and EBITDA by 6% in the last fiscal year.
In the most recent fiscal year, IQVIA reported gross margin of 33%, EBITDA margin of 23%, and net margin of 13%.
IQVIA Margins
IQVIA Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
IQVIA Operational KPIs
IQVIA's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
IQVIA's Rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IQVIA's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
IQVIA Competitors
IQVIA competitors include Veeva, GE HealthCare, Roper Technologies, Sartorius, Samsung BioLogics, Divi's Laboratories, Wuxi Biologics, Lonza Group, IDEXX Laboratories and Wuxi AppTec.
Most IQVIA public comparables operate across Contract Research & Manufacturing, Health Data & Analytics, Healthcare Software, BioTech, B2B SaaS, HealthTech and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.6x | 7.3x | 16.7x | 16.1x | |||
| 1.8x | 1.7x | 9.7x | 9.9x | |||
| 5.7x | 5.5x | 14.2x | 13.9x | |||
| 6.4x | 6.3x | 20.9x | 20.5x | |||
| 13.6x | 12.7x | 22.8x | 23.3x | |||
| 16.2x | 15.8x | 44.0x | 48.2x | |||
| 5.1x | 4.8x | 12.5x | 12.5x | |||
| 5.8x | 5.6x | 18.3x | 17.7x | |||
This data is available for Pro users. Sign up to see all IQVIA competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by IQVIA
IQVIA has acquired 11 companies to date.
Last acquisition by IQVIA was on October 8th 2023. IQVIA acquired OpenApp for undisclosed valuation.
Latest Acquisitions by IQVIA
| Description | OpenApp is a Dublin-headquartered software firm specializing in open-source development for healthcare applications. The company delivers patient registry systems, geographic information platforms, health intelligence tools, and document management solutions for medical providers. Clients in Ireland and Europe rely on OpenApp's custom integrations with electronic health records and compliance standards like GDPR and HIQA regulations. Founded in 2005, it employs agile methodologies to build scalable web and mobile apps using technologies such as PostgreSQL, React, and Docker. OpenApp supports public health initiatives through projects with HSE Ireland and private clinics. | Pharmaspectra delivers specialized data analytics and insights for medical affairs teams in pharmaceuticals and biotechnology. Boston-based, the company aggregates real-world evidence from field medical interactions, congress activities, and key opinion leader engagements. Pharmaspectra serves clients like Pfizer and Novartis by generating benchmarks on HCP interactions and publication strategies through its proprietary platform. | AllCare Plus Pharmacy is a specialty pharmacy in Northborough, Massachusetts, specializing in complex medication management for chronic conditions including rheumatoid arthritis, hepatitis C, and oncology. The pharmacy provides 24/7 clinical support, adherence packaging, and compliance programs like prior authorization assistance. Accredited by URAC, it dispenses biologics and infused therapies with delivery services across New England. | Linguamatics is a software provider of natural language processing text mining tools for extracting key facts and relationships from extensive document sets. Its I2E platform supports applications in business intelligence, competitive analysis, life sciences research, and social media monitoring like Twitter. Cambridge-based since 1999, the company serves pharmaceutical firms and intelligence agencies with high-performance querying across unstructured data sources at linguamatics.com. | |
| HQ Country | |||||
| HQ City | Dublin | New York City, NY | Worcester, MA | Cambridge | |
| Deal Date | 8 Oct 2023 | 1 Aug 2022 | 16 Sep 2020 | 12 Feb 2019 | |
| Valuation | undisclosed | $100M | undisclosed | $65M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all IQVIA acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by IQVIA
IQVIA has invested in 7 companies to date.
Latest investment by IQVIA was on April 14th 2020. IQVIA invested in ObvioHealth in their $17M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by IQVIA
| Description | ObvioHealth is a New Jersey-headquartered digital health firm conducting decentralized clinical trials via mobile apps. Participants engage remotely using smartphones for data collection, integrating wearables like Apple Watch and Fitbit. Features include chatbots, video calls, lab scheduling, and PayPal reimbursements, supporting site-less and hybrid studies worldwide. | RxWare is a SaaS provider helping pharmaceutical manufacturers streamline patient access to therapies via the Patient Gateway platform. Founded in 2013, the vendor-neutral system connects ePrescribing platforms, manufacturer hubs, specialty pharmacies, affordability programs, system integrators, and nursing services. RxWare facilitates prior authorizations, benefit verifications, and free trial fulfillment, reducing therapy start times and improving adherence for brands in oncology, rare diseases, and specialty areas. | BC Platforms is a Helsinki-headquartered data technology provider for life sciences and healthcare. Its Data Access Platform enables access to over 22 million life-years of curated patient data, including real-world data, clinical records, genomics, and omics datasets from global partners. The company offers data-as-a-service to pharmaceutical firms like AstraZeneca and Novartis, supporting R&D from discovery to post-market surveillance. Its technology ensures compliance with privacy laws across jurisdictions and integrates with standards like FHIR and GA4GH. BC Platforms also delivers clinical decision-support tools for genomics analysis to healthcare providers worldwide. | Octopus.Health is a Tel Aviv-based patient engagement platform that deploys AI-driven Healthcare Personal Assistants for millions of patients. The technology uses machine learning algorithms to deliver tailored proactive healthcare plans and improve patient adherence. Founded in 2017, the company focuses on population health management through advanced analytics. | |
| HQ Country | |||||
| HQ City | New York City, NY | Wilmington, DE | Zurich | Tel Aviv | |
| Deal Date | 14 Apr 2020 | 21 Jan 2020 | 18 Dec 2019 | 1 Oct 2019 | |
| Round | Series A | Series A | Series C | Seed | |
| Raised | $17M | $6M | $15M | $6M | |
| Investors | Ayala; IQVIA; SPRIM; Tikehau Capital | IQVIA; Windham Venture Partners | Debiopharm Innovation Fund; IQVIA; Tesi | IQVIA | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all IQVIA investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IQVIA
| When was IQVIA founded? | IQVIA was founded in 2016. |
| Where is IQVIA headquartered? | IQVIA is headquartered in United States. |
| How many employees does IQVIA have? | As of today, IQVIA has over 93K employees. |
| Who is the CEO of IQVIA? | IQVIA's CEO is Ari Bousbib. |
| Is IQVIA publicly listed? | Yes, IQVIA is a public company listed on NYSE. |
| What is the stock symbol of IQVIA? | IQVIA trades under IQV ticker. |
| When did IQVIA go public? | IQVIA went public in 2013. |
| Who are competitors of IQVIA? | IQVIA main competitors include Veeva, GE HealthCare, Roper Technologies, Sartorius, Samsung BioLogics, Divi's Laboratories, Wuxi Biologics, Lonza Group, IDEXX Laboratories, Wuxi AppTec. |
| What is the current market cap of IQVIA? | IQVIA's current market cap is $31B. |
| What is the current revenue of IQVIA? | IQVIA's last 12 months revenue is $17B. |
| What is the current revenue growth of IQVIA? | IQVIA revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of IQVIA? | Current revenue multiple of IQVIA is 2.7x. |
| What is the current EBITDA of IQVIA? | IQVIA's last 12 months EBITDA is $4B. |
| What is IQVIA's EBITDA margin? | IQVIA's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of IQVIA? | Current EBITDA multiple of IQVIA is 11.6x. |
| What is the current FCF of IQVIA? | IQVIA's last 12 months FCF is $2B. |
| What is IQVIA's FCF margin? | IQVIA's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of IQVIA? | Current FCF multiple of IQVIA is 20.8x. |
| How many companies IQVIA has acquired to date? | As of June 2026, IQVIA has acquired 11 companies. |
| What was the largest acquisition by IQVIA? | $200M acquisition of STI Technologies on 23rd February 2017 was the largest M&A IQVIA has done to date. |
| What companies IQVIA acquired? | IQVIA acquired STI Technologies, Advanced Health Media, Pharmaspectra, Linguamatics, Themis Analytics, AllCare Plus Pharmacy, Polaris, Pilgrim Quality Solutions, OpenApp, Aileron Solutions, and 1 other company. |
| In how many companies IQVIA has invested to date? | As of June 2026, IQVIA has invested in 7 companies. |
| What was the last IQVIA investment? | On 14th April 2020 IQVIA invested in ObvioHealth, participating in a $17M Series A round, alongside Ayala, SPRIM, and Tikehau Capital. |
| In what companies IQVIA invested in? | IQVIA invested in COTA Healthcare, ObvioHealth, BC Platforms, Belong.Life, RxWare, Octopus.Health, and Naxions. |
See public comps similar to IQVIA
Lists including IQVIA
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




